.
MergerLinks Header Logo

Announced

Completed

Medical Marijuana-backed AXIM Biotechnologies completed the acquisition of Sapphire Biotech.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Synopsis

Edit

Medical Marijuana-backed AXIM Biotechnologies, a researcher, developer, and producer of cannabinoid-based pharmaceutical and nutraceutical products, completed the acquisition of Sapphire Biotech, an oncology research and development company. Financial terms were not disclosed. "Sapphire Biotech has already proven itself to have great potential in just the one year since its founding. We look forward to bringing them into our family of companies and helping them further their efforts in the field of oncology. It is very exciting to announce that Sapphire Biotech has both a diagnostic application as well as a promising oncology treatment in their arsenal. This acquisition marks a transformation of AXIM while aligning with the therapeutic cannabinoid analog space," Stuart Titus, Medical Marijuana CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US